The Medicare GLP-1 Bridge

Last reviewed 2026-Aug-20 · 6 min read

For the first time, Medicare beneficiaries can get certain GLP-1 medicines for weight management at a fixed low price. This page is what it is, who it covers, and the three pieces of fine print that change the maths.

The basics

The Medicare GLP-1 Bridge is a time limited demonstration run by the Centers for Medicare and Medicaid Services.

  • Cost: fifty dollars for a monthly supply.
  • Runs: 1 July 2026 to 31 December 2027.
  • Drugs named by CMS: Foundayo, Wegovy in injection and tablet form, and Zepbound KwikPen.

Who qualifies

You need to be enrolled in Medicare Part D drug coverage, specifically either:

  • a standalone prescription drug plan, or
  • a Medicare Advantage plan that includes prescription drug coverage, meaning an HMO, HMO point of service, or local or regional PPO with drug coverage.

CMS directs beneficiaries to check eligibility through Medicare.gov. Because this operates outside the usual Part D flow, your plan did not have to opt in, and it carries no risk on the arrangement.

The three pieces of fine print

This is the part that is almost never reported, and it matters if you take other medicines.

1. The Part D deductible does not apply. Good news, taken alone.

2. The fifty dollars does not count toward your true out of pocket total. This is the one to understand. Part D has phases, and what you spend normally pushes you toward the catastrophic phase where your other drug costs drop. Money spent through the Bridge does not move you along that track. If you take several expensive medicines, that is a real consideration.

3. There is no low income subsidy attached. If you receive Extra Help with your Part D costs, that assistance does not apply to the Bridge price.

None of this makes it a bad deal. Fifty dollars a month for an approved GLP-1 is a substantial change from where things stood in 2025. It is simply not the same as ordinary Part D coverage, and it should not be planned as though it were.

What comes after it

The Bridge is explicitly a bridge. CMS has said the extension through 2027 lets it collect utilisation data to share with Part D plan sponsors ahead of possible implementation of BALANCE.

BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. Under it:

  • Participation is voluntary for manufacturers, state Medicaid agencies and Part D plans.
  • CMS negotiates GLP-1 pricing and coverage terms on behalf of state Medicaid agencies and Part D sponsors.
  • State Medicaid agencies can join from May 2026 through 1 January 2027.
  • The Part D performance period runs 1 January 2027 to 31 December 2031.
  • Participating Part D sponsors must ensure no covered patient pays more than fifty dollars per 28 or 30 day supply in total out of pocket cost in the initial coverage phase, from an in-network pharmacy.
  • It pairs medication with lifestyle support, covering reduced calorie diet and increased physical activity.

So the direction of travel is that a fifty dollar ceiling becomes the norm for participating plans rather than a temporary demonstration.

What this means practically

If you are on Medicare and paying cash for a compounded GLP-1, check this first. A fifty dollar copay for an FDA approved product is a different proposition from a cash price for a product the FDA has not reviewed.

If you are on Medicare and were told these drugs are not covered, that advice may predate 1 July 2026.

If you are not on Medicare, this route is not available to you, and the relevant comparison is between your commercial insurance, federal cash pricing, and compounded.

What to ask

  • Am I enrolled in a plan type that qualifies?
  • Which of the named products is right for me?
  • Given my other prescriptions, does the true out of pocket exclusion affect my year?
  • Will my plan be participating in BALANCE from 2027?
  • What happens to my access when the Bridge ends on 31 December 2027?

Sources

  • Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
  • Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge, information for Part D plans and for pharmacies
  • Centers for Medicare and Medicaid Services, BALANCE Model and Request for Applications
  • Centers for Medicare and Medicaid Services, press release on $50 monthly access to GLP-1 medications

How we verify: see /how-we-verify.

Keep reading

All four ways to pay compared, at /guides/how-to-pay-for-glp1.

Whether Medicare covers Wegovy and Zepbound outside the Bridge, at /guides/does-medicare-cover-wegovy-zepbound.